Express Pharma

JUNE 13, 2024

The amyotrophic lateral sclerosis (ALS) market across the 8MM (8MM: the US, France, Germany, Italy, Spain, the UK, Japan, and Canada) is projected to grow at a compound annual growth rate (CAGR) of 15 per cent from $317 million in 2019 to $1.28 billion in 2029, forecasts GlobalData.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Compounding 98

Express Pharma

OCTOBER 16, 2024

The CRO sector in India, growing at a compound annual growth rate (CAGR) of 10.75 Similarly, India’s pharmaceutical contract manufacturing market is expected to increase at a CAGR of 14.67 billion by 2029 (3). per cent, is projected to reach $2.5 billion by 2030 (2). per cent, hitting $44.63

Biosimilars 103

Biosimilars Compounding Pharmaceutical Companies Pharmaceutical Companies 103

Pharmaceutical Technology

JANUARY 10, 2023

billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%. billion in 2029, although its sales growth is likely to continue beyond 2029. GlobalData expects that the T2D market will see significant growth from 2019–29, with the 9MM having a total of $45.9

Biosimilars 52

Biosimilars Labelling Diabetes Compounding 52

Viseven

JANUARY 15, 2025

in 2029 , with a compound annual growth rate of 27.9%. In 2024 , the top 20 pharmaceutical companies have already announced that they are actively researching uses for AI in R&D. In life sciences, chatbots and virtual assistants can be used by pharmaceutical companies to improve communication with patients.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Compounding Communication 52